Pre-made Cantuzumab Ravtansine benchmark antibody (Whole mAb ADC, anti-MUC1 therapeutic antibody, Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).[1] It uses a more hindered disulfide linkage than cantuzumab mertansine.[2]